Biomapas Buys Alira Health's CMC Business, Regeneron to Sequence 75,000 Multiethnic Cohort Samples
By Bio-IT World Staff
November 21, 2026 | Cradle expands work with argenx; Tesorai raises $5.3 million for its proteomics data platform; Sutter Health launches LATE dementia biobank registry; 10x Genomics launches agentic AI for single cell analysis; and more.
Noetik announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to advance cancer biology world models. Under the collaboration, Noetik gains access to proprietary data covering a range of cancers, collected during routine care from tens of thousands of patients, anchored by MSK's Clinicogenomic Harmonized Oncologic Real-World Dataset (CHORD) and curated by MSK's Department of Pathology and Laboratory Medicine. The data will be combined with Noetik's proprietary multimodal patient tumor datasets for both model pre-training and post-training. Goals include improving therapeutic response prediction, enhancing clinical outcomes and supporting target discovery. Noetik's OCTO foundation models are designed to match therapeutic targets to patient populations and predict clinical efficacy. Financial terms were not disclosed; MSK holds financial interests in Noetik. Press release.
Tesorai announced $5.3 million in seed funding, bringing its total funding to $8 million. Investors include Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures and ZAKA. The San Diego company's platform includes Tesorai Search, which processes raw mass spectrometry data in the cloud; Tesorai Chat, which runs downstream analyses through conversational prompts; and Tesorai Trove, a catalog of thousands of curated public proteomics datasets. In August, the team recovered the Alzheimer's marker p-tau217 from the raw data of five published brain studies that had not reported it. The funding will support work with biopharma and research customers, partnerships across the life sciences tools industry, and extension of the platform beyond proteins to other molecular data. Press release.
The Keck School of Medicine of USC announced that the Multiethnic Cohort (MEC) Study will add whole exome sequencing data for nearly 75,000 de-identified participant samples, with Regeneron Genetics Center funding and conducting the analysis. The MEC, a collaboration between Keck's Center for Genetic Epidemiology and the University of Hawaiʻi, began recruiting in 1993 and includes more than 215,000 adults in Southern California and Hawaiʻi, with genetic data from African American, Japanese American, Latino, Native Hawaiian and white participants. The study has mainly relied on genome-wide association studies; exome sequencing can identify rare variants those studies miss. Researchers plan to study copy number variation and test whether variants linked to one cancer affect others. Sequencing is expected to finish in 2027. Press release.
Cradle announced that argenx is expanding its use of Cradle's AI-driven protein engineering platform to more scientists and antibody discovery programs following results from its initial work with the platform. argenx has used the platform to improve existing lead candidates and generate new antibody candidates, with designs targeting multiple properties including target affinity and selectivity. argenx scientists run repeated design, test and learn cycles, exploring sequence space beyond their starting candidates and running designs independently. Cradle's platform combines AI-driven engineering, active learning from experimental data and multi-property optimization, and is used by more than 80 active R&D programs across pharmaceutical, industrial biotech, agriculture and consumer goods companies. Financial terms were not disclosed. Press release.
Sutter Health announced the launch of the LATE Biobank Registry to support research into limbic-predominant age-related TDP-43 encephalopathy (LATE), a form of dementia that can mimic Alzheimer's disease but involves abnormal buildup of the TDP-43 protein in brain areas important for memory. LATE currently has no specific biomarkers or known treatments, and autopsy studies show LATE pathology in about 40% of people aged 80 and older. The registry, which opened in May 2026, collects blood, cerebrospinal fluid and clinical data over time from patients who meet clinical criteria for LATE. At the time of abstract submission, researchers had identified 21 eligible patients, six of whom had consented. Early findings are being presented at the Clinical Trials on Alzheimer's Disease conference in Boston. Press release.
Biomapas announced the acquisition of the Chemistry, Manufacturing and Controls (CMC) business of Alira Health. The Boston-based team of more than 35 CMC experts will form the foundation of Biomapas North America, the group's new US business. The team provides outsourced clinical manufacturing, quality assurance oversight, CMC regulatory strategy and filings, and project management, with expertise in complex biologics including monoclonal antibodies, antibody-drug conjugates, oligonucleotides and cell therapies, as well as small molecules and peptides. It has supported more than 90 clients across the US and Europe. The CMC line adds to Biomapas' regulatory affairs, pharmacovigilance, clinical development, and digital and consulting services. The deal follows Biomapas' acquisitions of Delta PV in 2025 and Pinnaxis in 2026. Press release.
Laverock Therapeutics announced the appointment of Parker Moss as chief executive officer and board member, and Paul J. Sekhri as executive chairman. The two will lead the London-based company through its transition to clinical stage, including a Series A financing planned for 2027. Moss most recently led a $150 million investment in RNA design and manufacturing technology at Wellcome Leap's R3G programme and previously led corporate development at Exscientia and the cancer programme at Genomics England. Sekhri is chairman, president and CEO of vTv Therapeutics and was previously chairman of Longboard Pharmaceuticals. Founder David Venables will step down as CEO on December 31. Laverock's programmable gene control platform uses recoded miRNAs, and the company is developing ex vivo and in vivo CAR-T programs. Press release.
The Walter and Eliza Hall Institute of Medical Research (WEHI) announced it will lead a project to develop a personalized gene therapy platform for rare blood and immune disorders caused by single-letter DNA mutations, supported by an A$5 million grant from Australia's Medical Research Future Fund. The approach uses a lab-grown patient avatar built from each patient's blood sample to test whether a specific genetic correction restores normal cell function. The method uses prime editing, with editing components packaged as mRNA in lipid nanoparticles for delivery to blood stem cells in the bone marrow. Partners include Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Royal Children's Hospital and the University of Queensland. Over five years, the team aims to deliver a Phase I clinical trial-ready package, including manufacturing and safety testing. Press release.
10x Genomics announced the launch of Sentira Single Cell, a cloud-based application that uses an AI agent to analyze Chromium single cell data through a natural language interface. Researchers can bring their own question or hypothesis or ask the agent to propose hypotheses from their data; the agent then drafts an analysis plan for review, runs the analysis, returns results and documents conclusions. Each analysis is saved in an editable notebook recording the methods and code used. Built on 10x Cloud, the application runs multiple analyses in parallel and is powered by Anthropic's Claude models. Sentira Single Cell is available now with consumption-based pricing and expands the Sentira platform introduced in September; Sentira Spatial Analysis is in early access. Press release.


